BioProcess International

Allogeneic cell therapies would seem to provide a scalable alternative to autologous products that raise significant obstacles for process economics and logistics. As contributors to this eBook show, technical advances are happening in the field, but the biopharmaceutical industry will also need to expand allogeneic infrastructure to bring such therapies to their intended patient populations. This eBook highlights a couple key areas in which cell-therapy developers and manufacturers can finish laying the foundation needed to make allogeneic therapies sufficiently scalable and commercially viable.

From scale-up pitfalls to tech transfer nightmares, learn how emerging biotech companies can avoid costly mistakes when selecting and working with CDMOs.

Cell therapy programs rarely lose momentum because of a single challenge. More often, small gaps across process development, analytics, and GMP readiness create delays that become harder to address later. This special report explores how integrating development, manufacturing, and quality early can reduce risk and support a smoother path to clinical manufacturing.

Autologous cell therapies face geographic access barriers, but hybrid distributed manufacturing and decentralized apheresis improve patient reach.

industry veterans explain why dethroning CHO cells is less about science and more about risk, money, and the courage to go first.

Connecting existing downstream steps delivers the value of continuous bioprocessing, says executive Jon Coffman at BioProcess International in Boston.

Alexander Seyf, CEO of Autolomous, shares thoughts about the growing biotech economy in Australia.

NIBRT and San Jacinto College's biotech center in Houston train students for in-demand biomanufacturing and cell and gene therapy careers.

Autologous cell therapies face geographic access barriers, but hybrid distributed manufacturing and decentralized apheresis improve patient reach.

Subscribe to Receive our BPI Insider Newsletter